Reports Q2 revenue $3.66M, consensus $9.45M. Cash and cash equivalents totaled $133.1M as of June 30 compared to $83.7M as of December 31, 2023. The company said, “Revenue related primarily to our promotion agreement with Sandoz pursuant to which we share profits from the sale of Treprostinil Injection in the U.S. The decrease of $1.1M was primarily due to the impact of lower sales quantities in the current year as compared to the same period in the prior year.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Liquidia Technologies call volume above normal and directionally bullish
- Liquidia files to sell 7.32M shares of common stock for holders
- Liquidia initiated with a Perform at Oppenheimer
- Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)